IDT launches oPools Oligo Pools

19 Aug 2019

The longest, highest fidelity, and ready-to-use custom oligo pools on the market.

Integrated DNA Technologies (IDT) has launched oPools Oligo Pools – ready-to-use pools of high-quality DNA oligos up to 350 nucleotides long. Thanks to its industry-leading proprietary manufacturing processes and 30 years of dedication to exceptional quality products, IDT is able to provide oligo pools unparalleled in uniformity at yields that accelerate experiments by eliminating time-consuming and bias-producing PCR amplification steps required by other commercially available pools.

IDT launches oPools Oligo Pools

Pooled oligos are widely used in high-throughput workflows in synthetic biology, diagnostic development, and drug discovery. For optimum performance, such pools must be uniformly comprised of full-length oligos of the highest possible fidelity (oligos of correct sequence and length). IDT’s proprietary manufacturing platform produces long oligos more accurately, rapidly, and reliably than any other DNA synthesis platform, enabling timely delivery of the highest fidelity and most uniform oligonucleotide pools available.

oPools' low error rate of less than 1 in 2000 nucleotides, coupled with high per oligo yields, allow researchers to proceed immediately and confidently into their downstream workflows for projects including CRISPR library construction, protein screening, and gene assembly. For synthetic biologists, quick access to affordable, high-quality oligo pools that can go directly into their pipeline without the hands-on time required for PCR amplification allows for faster and more impactful “Design, Build, Test” cycles so critical to discovery.

Early adopters of the product offering have benefitted from the high-quality oPools for their applications, including ArcherDX, a molecular technology company dedicated to developing breakthrough solutions that advance personalized genomic medicine. Josh Stahl, Chief Scientific Officer of ArcherDX, commented: “ArcherDX evaluated several comparable product offerings from array-based providers, and the oPools from IDT were the best solution available to deliver the performance, speed, and ease-of-use necessary to meet our exacting requirements.”

Unlike suppliers that opt for array or silicon chip-based batch synthesis, IDT employs a unique, solid-support manufacturing platform that individually synthesizes every oligo. This delivers the highest percentage of full-length DNA in the industry. IDT’s manufacturing approach also ensures that each species of oligo is represented and at greater uniformity in the resulting pool allowing for a more complete experiment downstream. For IDT, 95% of sequences in oPools Oligo Pools are represented within 1.5x of the mean, compared to 90% within 4x of the mean for a comparative supplier.

Trey Martin, President of IDT, commented: “IDT has historically avoided the traditional pools market due to our capacity being fully booked. Two years into our 6th-generation synthesis platform, we have alleviated all capacity concerns and are thrilled to offer our unique take on oligo pools. They leverage the ultra-high fidelity of IDT synthesis to give heretofore unobtainable experimental results from the traditional microarray-driven approach. We have been in beta testing for 6 months and customers are delighted with the results. Our pool deliveries are in picomoles, eliminating the need to do any pre-amplification or other pre-work before the pool can be used. With lengths up to 350 bases and error rates below one per 2kB, these are the same oligos that IDT relies on for our own high-throughput gene assembly processes.”

IDT’s oPools are ready-to-run, affordable pools of customized single-stranded DNA sequences between 40-350 nt in length. There is no minimum order, pools are compatible with downstream cloning methods, and have a short turnaround time of just four to seven business days from ordering to delivery. oPools™ unparalleled concentration, uniformity, and low error rates assure high target specificity and provide researchers with the utmost confidence in results.

Read More

Related news

FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

10 Sep 2019

Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.

Read more 
BioCity backs world's first Rx to OTC switch incubator

BioCity backs world's first Rx to OTC switch incubator

5 Sep 2019

Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.

Read more 
Dutch company receives €20 million for skin cancer diagnostic test

Dutch company receives €20 million for skin cancer diagnostic test

3 Sep 2019

The test can accurately predict the risk of having metastases present in the lymph nodes without having to undergo surgery to remove lymph nodes.

Read more 
AbbVie axes Rovalpituzumab Tesirine R&D program

AbbVie axes Rovalpituzumab Tesirine R&D program

2 Sep 2019

Independent Data Monitoring Committee recommended terminating the study due to lack of survival benefit.

Read more 
Improving anxiety-induced insomnia with lavender oil

Improving anxiety-induced insomnia with lavender oil

29 Aug 2019

New data shows pharmaceutical-quality lavender oil significantly improves anxiety-induced insomnia when taken as a daily capsule.

Read more 
Grant from Innovate UK to fund gel stabilisation technologies development

Grant from Innovate UK to fund gel stabilisation technologies development

28 Aug 2019

Atelerix Consortium awarded £267,000 Innovate UK Grant for collaboration with the Cell and Gene Therapy Catapult and Rexgenero on cell therapy stabilisation technologies.

Read more 
Exciting new vaccine targets killer disease TB

Exciting new vaccine targets killer disease TB

28 Aug 2019

Australian researchers produce early-stage vaccine which is inhaled into the lungs.

Read more 
Rapid adoption of Carterra’s LSA instrument drives European expansion

Rapid adoption of Carterra’s LSA instrument drives European expansion

20 Aug 2019

Company's antibody screening platform minimizes the risk of missing a blockbuster.

Read more 
FDA Approves rfxcel for Verification Router Service (VRS) Pilot

FDA Approves rfxcel for Verification Router Service (VRS) Pilot

15 Aug 2019

rfxcel, the global leader in supply chain compliance and serialization solutions, has been approved by the U.S. Food and Drug Administration (FDA) to conduct a pilot to extend the testing of the Verification Router Service (VRS) for saleable returns.

Read more 
rfxcel Awarded ISO 9001:2015 Certification

rfxcel Awarded ISO 9001:2015 Certification

14 Aug 2019

rfxcel, the leader in track and trace solutions for global supply chains announced that it is now ISO 9001:2015 certified for Quality Management Systems.

Read more